Implication of Complement System and its Regulators in Alzheimers Disease
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is an age-related neurodegenerative disease that affects approximately 24 million people worldwide. A number of different risk factors have been implicated in AD, however, neuritic (amyloid) plaques are considered as one of the defining risk factors and pathological hallmarks of the disease. Complement proteins are integral components of amyloid plaques and cerebral vascular amyloid in Alzheimer brains. They can be found at the earliest stages of amyloid deposition and their activation coincides with the clinical expression of Alzheimer's dementia. This review emphasizes on the dual key roles of complement system and complement regulators (CRegs) in disease pathology and progression. The particular focus of this review is on currently evolving strategies for design of complement inhibitors that might aid therapy by restoring the fine balance between activated components of complement system, thus improving the cognitive performance of patients. This review discusses these issues with a view to inspiring the development of new agents that could be useful for the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“Genetic predisposition accounts for only 5-10% of the risk of AD and is most pronounced in those developing disease at an early age [5, 11].”
BackgroundMCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287 · cited 1×
“Other complement activators, such as amyloid P, C-Reactive Protein (CRP) and Hageman factor, were found in AD lesions and their potential role for the progression of the disease has been reviewed elsewhere [31].”
BackgroundNonsteroidal anti-inflammatory drugs in Alzheimer's disease
Rich, J. B., Rasmusson, D. X., Folstein, M. F., Carson, K. A., Kawas, C., & Brandt, J. (1995) · Neurology · doi:10.1212/wnl.45.1.51 · Cited by 446 · cited 1×
“Different inflammatory markers such as activated microglia and astrocytes, elevated levels of various cytokines and complement activation products are found in the AD brain [41].”
BackgroundProminent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
Wyss-Coray, T., Yan, F., Lin, A. H.-T., Lambris, J. D., Alexander, J. J., Quigg, R. J., & Masliah, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162350199 · Cited by 446 · cited 8×
“More recently, a protective role of complement in AD was demonstrated in human APP transgenic mice; when complement was blocked by expression of soluble Crry (a rodent CReg with inhibitory activities similar to human CD46 and CD55) [63], mice expressing soluble Crry had a 2-3-fold increase in A accumulation and neuron…”
BackgroundInfluentialMaier, M., Peng, Y., Jiang, L., Seabrook, T. J., Carroll, M. C., & Lemere, C. A. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0829-08.2008 · Cited by 323 · cited 1×
“This speculation is supported by a recent in vivo study in C3 deficient APP transgenic mice that demonstrated accelerated plaque deposition and neurodegeneration compared to C3 sufficient animals [30].”
Result
Cited by
Sarma, J. V., & Ward, P. A. (2011) · Cell and Tissue Research · doi:10.1007/s00441-010-1034-0 · Cited by 974
ApoE4: an emerging therapeutic target for Alzheimer’s disease
Safieh, M., Korczyn, A. D., & Michaelson, D. M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1299-4 · Cited by 449
Microglia and Inflammation in Alzheimers Disease
Mandrekar-Colucci, S., & Landreth, G. E. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012071 · Cited by 421
Upadhya, R., Zingg, W., Shetty, S., & Shetty, A. K. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.017 · Cited by 282
Role of inflammatory molecules in the Alzheimer's disease progression and diagnosis
Bagyinszky, E., Giau, V. V., Shim, K., Suk, K., An, S. S. A., & Kim, S. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.03.031 · Cited by 262
Metadata
- Authors
- Kolev, M., Ruseva, M., Harris, C., Morgan, B., & Donev, R.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-03-01
- Volume
- 7
- Issue
- 1
- Pages
- 1-8
- ISSN
- 1570-159X (ISSN-L)
- OpenAlex
- W2161996060
- Cited by
- 77
- References
- 5
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Implication of Complement System and its Regulators in Alzheimers Disease. https://app.cochat.ai/papers/10.2174/157015909787602805
- The paper
- Kolev, M., Ruseva, M., Harris, C., Morgan, B., & Donev, R. (2009). Implication of Complement System and its Regulators in Alzheimers Disease. Current Neuropharmacology. https://doi.org/10.2174/157015909787602805
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.